Enzo Biochem Inc
NYSE:ENZ

  • LAST PRICE
    2.4300
  • TODAY'S CHANGE (%)
    0.0500 (2.1008%)
  • Bid / Lots
    2.2900/ 1
  • Ask / Lots
    2.6000/ 1
  • Open / Previous Close
    2.3600 / 2.3800
  • Day Range
    2.3100
    2.4500
  • 52 Week Range
    1.0000
    3.0600
  • Volume
    209,576

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Healthcare Facilities Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
ENZ
Enzo Biochem Inc
120.7M
-3.4x
---
TALK
Talkspace Inc
112.7M
-1.4x
---
BDSX
Biodesix Inc
145.0M
-1.2x
---
STRM
Streamline Health Solutions Inc
103.3M
-9.3x
---
BGLC
BioNexus Gene Lab Corp
93.8M
-843.6x
---
MYNZ
Mainz Biomed NV
91.0M
-3.6x
---
As of 2023-04-01

Company Information

Enzo Biochem, Inc. is an integrated diagnostics, clinical lab and life sciences company. The Company is focused on delivering and applying advanced technology capabilities to produce products and services that enable its customers to meet their clinical needs. The Company operates through three segments. Enzo Clinical Lab segment is a clinical reference laboratory, which provides a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. Enzo Life Sciences segment manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. Enzo Life Sciences has developed products used in the identification of genomic information by laboratories around the world. Enzo Therapeutics is a biopharmaceutical venture that has developed multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases.

Contact Information

Headquarters
60 EXECUTIVE BLVDFARMINGDALE, NY, United States 11735
Phone
516-755-5500
Fax
---

Executives

Independent Chairman of the Board
Mary Tagliaferri
Chief Executive Officer, Director
Hamid Erfanian
Interim Chief Financial Officer
Patricia Eckert
Chief Operating Officer
Kara Cannon
General Counsel, Secretary
Matthew Kupferberg

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$120.7M
Revenue (TTM)
$81.1M
Shares Outstanding
49.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.03
EPS
$-0.72
Book Value
$1.12
P/E Ratio
-3.4x
Price/Sales (TTM)
1.5
Price/Cash Flow (TTM)
---
Operating Margin
-42.09%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.